Abstract: Carney complex (CNC) is a rare dominantly inherited multiorgan tumoral disorder that includes Cushing syndrome (CS). To establish the Mayo Clinic experience with the CS component, including its clinical, laboratory, and pathologic findings, we performed a retrospective search of the patient and pathologic databases of Mayo Clinic in Rochester, MN, for patients with CNC and clinical or laboratory findings of CS. Thirty-seven patients with CNC were identified. Twenty-nine had clinical, pathologic, or laboratory evidence of an adrenocortical disorder. Seventeen had classic CS; 15 underwent bilateral, subtotal, or partial unilateral adrenalectomy, and 2 had no treatment. Pathologically, the glands were normal sized or slightly enlarged with multiple small (1 to 4 mm), brown, black, and yellow micronodules (primary pigmented nodular adrenocortical disease; PPNAD). Three glands each had a mass: a 2 cm adenoma, a 1.5 cm macronodule, and an unencapsulated 1.8 cm myelolipoma. Fourteen of the patients were alive at follow-up, and 3 were deceased; 2 of the latter had PPNAD at autopsy, and the third had PPNAD at surgery. Twelve patients without clinical features of classic CS had abnormal adrenocortical testing results; none developed classic CS during follow-up (mean, 10 y). Autopsy findings in 1 showed bilateral vacuolated cell cortical hyperplasia.
I
n 1932, in a report based on clinical and pathologic observations in 12 patients, Harvey Cushing 1 enunciated the findings known today as Cushing syndrome (CS). The clinical findings were adiposity, kyphosis, amenorrhea in female patients and impotence in male patients, hypertrichosis, purple lineae atrophicae, osteoporosis, and skin abscesses and ulcers. The pathologic findings included pituitary tumors and unilateral and bilateral adrenal enlargement.
In 1939, 17-year-old fraternal twins were evaluated at Mayo Clinic in Rochester, MN. They had the clinical features described by Cushing and also intense facial and body pigmented spots. Adrenal exploration in 1 of the twins showed "small adrenal glands with multiple small brown nodules." These findings were not mentioned by Cushing, and the twins were thought to have an "adrenocortical syndrome" different from that described by Cushing. In 1984, Shenoy et al 2 reported on 4 young Mayo Clinic patients who had CS and a bilateral adrenocortical pathology that they termed primary pigmented nodular adrenocortical disease (PPNAD). The adrenal glands were small and studded with brown and black cortical micronodules.
In 1985, Carney et al 3, 4 recognized that PPNAD was a component of a familial multiorgan tumoral syndrome that included pigmented skin lesions (lentiginosis and blue nevi), myxomas (cardiac, cutaneous, and mammary), and endocrine disorders (CS, acromegaly, and sexual precocity) and was subsequently referred to as Carney complex (CNC). 5 A provisional diagnosis of CNC was considered to be warranted when 2 of its components occurred in a characteristic manner 3 -when the lentiginosis affected the face and vermilion border of the lips, the cardiac tumor was multifocal and occurred in any or all cardiac chambers, and the endocrine neoplasms were multifocal and bilateral (the pituitary involvement was multifocal).
In 2000, Kirschner et al 6 discovered that CNC was caused by heterogenous inactivating mutations of PRKAR1A in >60% of affected patients. PRKAR1A, an apparent tumor-suppressor gene, is located at chromosome 17q22-24, encodes protein kinase A regulatory subunit 1a, and is a central component of the cyclic adenosine monophosphate signaling pathway.
CS has occurred in about 25% of patients with CNC. 7, 8 The syndrome requires treatment because of its serious long-term consequences. Herein, we describe the adrenocortical clinical, pathologic, and molecular genetic findings in the Mayo Clinic patients with CNC, focusing on the CS component.
PATIENTS AND METHODS
This study was approved by the Mayo Clinic Institutional Review Board (protocols 979-01 and 14-3722). We searched the clinical, pathologic, and autopsy records at Mayo Clinic in Rochester, MN, for patients who had 2 or more components of CNC. Information was recorded on the patients and their families, including clinical findings, adrenal imaging and laboratory results, PRKAR1A mutational status, treatment, pathologic findings, and follow-up. Histologic slides and paraffin blocks of surgical and necropsy adrenal glands were retrieved from the Mayo Clinic Tissue Registry Archives. Similar information and materials were obtained for relatives of the Mayo Clinic patients who had adrenal surgery at other institutions and were subsequently evaluated at Mayo Clinic. The study group included the grandchildren of 1 of the Mayo Clinic patients; they were evaluated at the National Institutes of Health (Bethesda, MD).
Categories of CS
Patients were categorized as having (1) classic CS, (2) subclinical CS, (3) possible CS, or (4) no CS. Patients with classic CS had (1) physical findings and symptoms, including weight gain (primarily abdominal); thick, purple-red abdominal striae; proximal muscle weakness; facial rounding and redness; hirsutism; and hypertension and (2) abnormal laboratory findings, including 24-hour urinary free cortisol excretion that exceeded the upper limit of the reference range, absence of diurnal variation in serum cortisol level, nonsuppressible blood cortisol levels after overnight dexamethasone administration, and suppression of baseline morning plasma corticotropin (ACTH) levels.
Patients with subclinical CS had some or none of the signs and symptoms of classic CS. Their cortisol levels were not suppressed with dexamethasone administration. Other findings included loss of diurnal serum cortisol variation and suppressed serum ACTH levels.
Patients with possible CS had (1) some of the clinical findings listed above and borderline results of 1 or more tests that define classic CS or (2) adrenal pathologic findings without symptoms or signs of CS or abnormal adrenal testing results. A patient included in this group had no symptoms or signs of CS and normal circulating levels of plasma cortisol; this patient's ectopic (spermatic cord) adrenal cortex was available for pathologic study.
Patients with no CS had no clinical or other evidence of CS and, thus, underwent no laboratory adrenal testing for it. Mild biochemical abnormalities could have been undetected in these patients.
Diagnostic Studies
Patients underwent adrenal and pituitary imaging when available. Adrenocortical laboratory testing included measurement of 24-hour urinary cortisol excretion, assessment of diurnal serum cortisol rhythm, measurement of percentage change in 24-hour urinary cortisol with dexamethasone administration, and measurement of plasma ACTH. Urinary ketosteroid and ketogenic steroid excretion was measured in some patients who presented before 1975.
For histologic and immunocytochemical study, the adrenal glands from surgical resection and necropsy and the adrenal biopsy specimens were immersed in 10% neutral buffered formalin and embedded in paraffin. Sections 4 mm thick were cut for hematoxylin-eosin and Masson trichrome staining and for immunostaining with antibodies to synaptophysin, inhibin-A, melan A, and CD56.
DNA for PRKAR1A mutation testing was extracted from peripheral blood leukocytes of 13 patients.
Treatment
Treatment of classic CS was surgical: bilateral adrenalectomy (12 patients-3 after initial unilateral adrenalectomy); subtotal adrenalectomy (2 patientsexcision of 1 adrenal gland and partial removal of the contralateral gland); and subtotal unilateral adrenalectomy (1 patient-partial removal of 1 adrenal gland). Two patients with classic CS and 12 with subclinical or possible CS received no treatment.
RESULTS

Clinical Findings
Thirty-seven patients with 2 or more components of CNC were identified. The group included the CNC index patient, who was recognized in 1984 from findings in a 1959 autopsy 9 and the dizygotic twins mentioned above, who were identified in 1989 from clinical photographs obtained 50 years earlier. 10 Of the 37 patients, 26 (70%) had classic CS, subclinical CS, or possible CS (Table 1 and Figs. 1-3 ), and 3 others (patients 27 to 29) had adrenal or ectopic adrenal pathologic findings typical of CNC but no CS. These 29 patients formed the study group. The other 8 patients, who were excluded from the study because they lacked clinical features of CS and had no laboratory testing for it, were followed for 2 to 49 years (mean, 19.5 y), but CS did not develop in any of them.
The sex and age of the study patients, their CNC components and other findings, family relationships, and PRKAR1A mutational status are shown in Table 1 . Seventeen patients (59%) had classic CS (1 was African American): 7 were 10 years or younger, 7 were aged 11 through 20 years, and 3 were older than 20. CS was the presenting finding for 2 of them (Figs. 1B, F) . The youngest (Figs. 1B-E) and oldest patients at diagnosis of CS were 2 and 45 years, respectively. Seven patients had adrenal surgery at Mayo Clinic; 8 were operated on at Figs. 2A, B) . Six patients had subclinical CS, and 6 had possible CS. Eighteen patients (62%) were members of 6 families in which CNC was transmitted as a dominant trait (Fig. 1A) . Some findings in 10 of the patients were reported previously. [9] [10] [11] [12] [13] [14] [15] [16] 
Adrenal and Pituitary Imaging and Laboratory Testing
Computed tomographic (CT) imaging (Supplementary Table, Supplemental Digital Content 1, http:// links.lww.com/PAS/A437) showed unilateral or bilateral adrenal micronodularity, with or without thickening of the gland(s) in 7 patients; unilateral thickening or unilateral nodule or unilateral mass with contralateral micronodularity in 1 patient each; and normal adrenals in 3 patients. Four patients had indeterminate results or did not have an imaging study. Nine patients had a pituitary tumor (3 had a growth hormone-producing adenoma resected). Results of the laboratory testing are shown in the Supplementary Table (Supplemental Digital Content, http://links.lww.com/PAS/A437).
Molecular Genetics
Six different PRKAR1A mutations were found among 12 of 13 patients (Table 1) . The gene was deleted in patient 17.
Treatment and Follow-up
Nine of the 17 patients with classic CS underwent primary bilateral adrenalectomy and were cured of all manifestations of the syndrome (Table 2) . Three others had recurrence of the syndrome after unilateral adrenalectomy and were cured with contralateral adrenalectomy. Two patients underwent subtotal adrenalectomy: Patient 11 ( Table 2 ) was cured of clinical manifestations of the A, At age 17 years, the patient's plump face was covered with small pigmented spots. B, At age 65 years, the face had lost its fullness and the facial pigmentation was less obvious. C, Cut surface of left adrenal gland at autopsy showed several dark micronodules (arrows). D, The left adrenal gland featured several micronodules (asterisks) and loss of normal cortical zonation. The capsule was intact. There was no extracapsular extension (hematoxylin-eosin). E, A cortical nodule had large and huge eosinophilic cells, many with lipochrome (arrows), and there was an exceptional cell with elongated crystal-type spaces (center) (hematoxylin-eosin). F, Synaptophysin staining. Upper, Two positive areas were seen; 1 was ovoid (asterisk). Lower, Heavily stained round paranuclear "bodies" (arrows) were seen along with cell membrane and cytoplasmic staining. G, CNC mucosal and skin lesions (patient 10). Upper, Mucocutaneous pigmentation. Middle, Lacrimal caruncular pigmentation (arrow). Lower, Cutaneous auricular nodule (myxoma). H, Cut surfaces of the left adrenal gland showed variably sized pigmented micronodules and oval elongated zones (arrows) and a 1.7 cm oval darkly pigmented lesion (myelolipoma) (asterisk) attached to the gland. I, Bottom left slice of adrenal in H showed an epicapsular mass of cortical cells with some fat (arrows) (hematoxylin-eosin). J, The gland had multiple micronodules staining strongly for synaptophysin (arrows). The myelolipoma was weakly stained for synaptophysin.
Pathology
The initial and study adrenal pathologic diagnoses are presented in Table 2 . The glands were generally normal size or slightly enlarged and retained their normal shape in the patients with classic CS. Total adrenal weight ranged from 6 to 13.7 g (mean, 9 g; normal range for adult, 8 to 9 g). The sectioned glands showed small (1 to 4 mm), brown, black, yellow, and red micronodules (Fig. 2) . The glands were enlarged, together weighing 13.5 g, and microscopically abnormal in patient 27, who did not have classic CS. Three patients each had a cortical mass: an encapsulated 2 cm adenoma (patient 17), an unencapsulated 1.5 cm macronodule (patient 27), and an unencapsulated 1.8 cm epicapsular myelolipoma (patient 10).
Hematoxylin-eosin-stained sections of the adrenals showed (1) enlarged eosinophilic cortical cells, some with lipochrome arranged in micronodules; (2) extranodular cortical atrophy or vacuolated cell hyperplasia (patients 4 to 8); (3) epicapsular and intracapsular extension of cortical hyperplasia, with the former sometimes connected with the cortex proper through breaks in the gland capsule (there was no infiltration of the medulla); and (4) benign cortical tumors (mentioned in the previous paragraph). According to combinations of findings, 12 patients had PPNAD with many micronodules, extranodular cortical atrophy, and slight intracapsular and epicapsular cortical extension, and 7 patients had PPNAD variant with scattered cortical micronodules, vacuolated cell cortical hyperplasia, and prominent in- Table 2 ) who were not treated were obtained at autopsy. The syndrome regressed spontaneously in patient 1. When reexamined at age 65 years, the patient had no clinical evidence of CS, but there was mild ACTHindependent adrenal autonomy. The patient's twin brother (patient 2; Table 2 ) died suddenly at age 44 years with acute hypertension (blood pressure, 230/130 mm Hg) after an inguinal hernia operation. Hospital notes included the following comments: "Needs an endocrinological work-up," "Historically, people called him 'redface'," and "Has anterior vertebral body flattening, suggesting decalcification." Both patients had PPNAD at autopsy. Patient 17 who had asynchronous bilateral adrenalectomy died suddenly at age 33 years. No cause was found at autopsy. The patient had vomiting and diarrhea for several days before death and reportedly had been taking steroid replacement.
The adrenal glands of 2 patients with possible CS were studied. Patient 27 (Table 1 and Figs. 3E-H) died at age 44 years of cardiac failure due to ischemic heart disease and sequelae of multiple operations for cardiac myxoma. Necropsy showed bilateral adrenal enlargement due to vacuolated cell hyperplasia, vacuolated cell micronodules, and a 1.5 cm eosinophilic pigmented macronodule. Patient 28 (Figs. 3A-D) (the index patient for CNC) died suddenly at age 33 years of mitral valve occlusion caused by a prolapsed left atrial myxoma. PPNAD and pituitary Crooke cells (an indicator of hypercortisolemia) were found at autopsy.
Immunoperoxidase staining results were available for 14 patients (the sections in 2 patients were not immunoreactive). Synaptophysin, inhibin-A, melan A, and CD56 (cell membrane) stained the micronodules in 13, 13, 8, and 5 patients, respectively; the extranodular cortex was positive for the stains in 10, 10, 10, and 7 patients, respectively; and the epicapsular cortex was positive in 12, 11, 8, and 8 patients, respectively. The adenoma in patient 17 stained for synaptophysin (patchy), inhibin-A and melan A, and CD56 (weakly). The associated extratumoral cortex was strongly positive for synaptophysin. The ectopic adrenal cortex in patients 7 and 29 was synaptophysin positive. The micronodules in the glands obtained at the autopsy of patient 1 were synaptophysin positive. The paraffin sections in the other 2 autopsied patients (patients 27 and 28) were not immunoreactive.
DISCUSSION
CS is usually caused by an ACTH-secreting pituitary tumor (about 80% of the cases). Infrequently, it results from a primary adrenal neoplasm, an adenoma, or (rarely) a carcinoma, and, exceptionally, it is caused by primary bilateral micronodular and macronodular adrenocortical hyperplasia resulting from genetic mutations: germline mutations of PRKAR1A, 6 PDE11A, 17 PDE8B, 18 PRKACA, 19 and ARMC5 20 and somatic mutations of both GNAS1 and PRKACA. 19, 21 Herein, we report the findings from the 29 Mayo Clinic patients with CNC and abnormal adrenocortical findings, including (1) different types of CS (persistent, cyclic, and ameliorative); (2) syndrome cure with different surgical interventions (total adrenalectomy, subtotal adrenalectomy, and partial unilateral adrenalectomy); (3) rare spontaneous resolution of the syndrome (patient 1); (4) several pathologic findings, PPNAD, PPNAD variant, and benign cortical neoplasms; (5) typical CNC-type adrenal pathology (PPNAD) but no CS (silent PPNAD) (patients 27 and 28); and (6) PPNAD in ectopic adrenal cortex (patients 7 and 29).
Radiologic and laboratory testing results were incomplete because of (1) unavailability of CT and measurement of serum cortisol and cortisol suppression testing when some of the patients were examined and (2) nonsystematic performance of the testing by multiple examiners. The CT imaging results (Supplementary Table, Supplemental Digital Content, http://links.lww.com/ PAS/A437) were not diagnostic. None of the patients had the "string of beads" appearance characteristic of PPNAD. 22 Half of those with classic CS had small nodules or thickening of the glands. Biochemically, the laboratory results showed that patients with classic CS had 23, 24 In the past, some patients who were treated with unilateral adrenalectomy had variable results, including unexpected "cure" of the CS for up to 9 years after unilateral adrenalectomy. 25 Three different surgical treatments were used in 15 of the 17 Mayo Clinic patients with classic CS. The other 2 patients (seen in 1939) were not treated (Table 2) . Twelve patients had bilateral total adrenalectomy and were cured of all manifestations of CS. Two patients underwent subtotal adrenalectomy: 1 (patient 11) was cured of the clinical manifestations of CS without need for corticosteroid replacement (mild adrenal autonomy remained); the other (patient 14) was cured of the clinical manifestations of the syndrome but had postoperative adrenal insufficiency. Patient 4 had subtotal unilateral adrenalectomy, was cured of CS, and did not need adrenal support. At follow-up of 1 of the untreated patients (patient 1) (Figs. 2A-D) , the CS (present at age 17) had regressed spontaneously. At age 65, she had no clinical evidence of CS (mild adrenal autonomy remained). At age 77, she died of pancreatic carcinoma: PPNAD was found at autopsy. The syndrome persisted in the other untreated patient (patient 2) for 27 years. He died suddenly at age 44. PPNAD was found at autopsy. The mild postoperative adrenal autonomy in patients 4 and 11 apparently did not cause adverse effects. The results of less than bilateral total adrenalectomy warrant reconsideration of the surgical treatment of CS in CNC.
The majority of the patients (12 of 13) with classic CS had a PRKAR1A mutation or deletion ( Table 1) . The mutations caused different clinical phenotypes, and different clinical phenotypes resulted from the same mutation (Table 1 and Figs. 1-3) .
On the basis of the relative prominence of the observations, the findings were classified as PPNAD (12 patients) or PPNAD variant (including the 5 members of family B [patients 4 to 8] and the sisters [patients 13 and 14] ). PPNAD histologic changes were found in accessory adrenal cortex in patients 7 and 29: Patient 7 had classic CS and histologically proven PPNAD variant, and patient 29 did not have CS, but it seems possible, likely perhaps, that the patient's orthotopic adrenal glands had functionally silent PPNAD.
The pathologic findings described in the previous 2 paragraphs are not peculiar to CNC-they have appeared in patients with mutations of PDE11A, PDE8B, and PRKACA, thereby indicating that they are common in germline-induced adrenal cortical hyperplasia and are perhaps characteristic of it. Nongenetic (ACTH)-induced cortical hyperplasia is different histologically, being confined within the gland capsule and thus raising the following question: Why does genetically driven hyperplasia extrude outside the capsule and ACTH-driven hyperplasia not extrude? The explanation may lie in the level of the cortex or a particular subset of cortical cells affected by the abnormal stimulus.
Although all the adrenal lesions encountered in the study were benign, adrenocortical carcinoma has been reported in 2 patients with CS in CNC. 25, 26 It is possible that these neoplasms evolved through progression of a micronodule to a macronodule (found in patient 26) to an adenoma (found in patient 17) and eventually to carcinoma. b-Catenin mutations have been found in adenomas in PPNAD and may be involved. 27 The synaptophysin-positive cells in the micronodules and the cortex were evidently a site of cortisol overproduction and secretion. Although the molecular events leading to this are unknown, apparently a malfunction in the normal pathway of cortisol synthesis or in an upstream mechanism regulated this. The large eosinophilic cells in the micronodules were variously (1) overactive with excessive secretion of cortisol, causing classic CS (patients 2 to 17); (2) overactive to a lesser degree and insufficient to cause classic CS (patients 18 to 23); (3) overactive (causing CS) with return to "normal" function (patient 1); and (4) normoactive (patient 27) with PPNAD in adrenocortical heterotopia.
Among the other conditions listed in Table 1 , pilonidal cyst, which was present in patients 1 and 2 (brother and sister), has been reported in 4 members of a family with CNC, 28 making the condition almost certainly a rare manifestation of the syndrome. Also, in patient 11, the follicular thyroid carcinoma, which was bilateral with cervical lymph node metastasis, is a very unusual presentation of the tumor, and this lesion may be another rare constituent of CNC.
CS is a serious component of a rare familial multiorgan tumoral disorder, CNC. Among the 37 Mayo Clinic patients with CNC, 17 had classic CS caused by primary bilateral adrenocortical pathology. The CS was cured with bilateral adrenalectomy, with subtotal adrenalectomy, and with partial unilateral adrenalectomy; it persisted untreated for almost 3 decades in 1 patient and regressed spontaneously in another. Two patients had PPNAD but no CS, indicating that the adrenal pathology was clinically silent.
